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To study the effects of de novo induction of ornithine decarboxylase (ODC) activity in adult, quiescent skin, we
generated transgenic mice in which the suprabasal expression of an inducible form of the ODC protein fused to a
modiﬁed estrogen receptor ligand-binding domain (ODCER) is driven by an involucrin promoter. After topical
treatment with the inducing agent 4-hydroxytamoxifen (4OHT), ODC activity and putrescine levels were dramat-
ically increased in the epidermis but not in the dermis of transgenic mice. 4OHT treatment stimulated both pro-
liferation as measured by bromodeoxyuridine incorporation in basal epidermal cells and differentiation shown by
increased expression of differentiation markers. Furthermore, induction of ODC activity did not rescue primary
epidermal keratinocyte cultures isolated from ODCER2 mice from a calcium-triggered DNA synthesis block, as
measured by [3H]thymidine incorporation. In vivo induction of epidermal ODC enzyme activity significantly stim-
ulated the vascularization of ODCER transgenic skin. Increased expression of interleukin-1b and keratin 6, markers
of keratinocyte activation seen in wound healing, was also observed in 4OHT-treated transgenic skin. These results
suggest that de novo suprabasal induction of ODC activity in adult mouse skin activates keratinocytes and stim-
ulates vascularization in the dermal layer in a manner similar to skin undergoing wound healing.
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Polyamines have long been known to be associated with
cell proliferation in both normal and neoplastic tissues (Ta-
bor and Tabor, 1984; Pegg, 1988). Ornithine decarboxylase
(ODC) is the initial rate-limiting enzyme involved in polya-
mine biosynthesis and is responsible for converting L-orni-
thine to putrescine. The polyamines spermidine and
spermine are the most cationic small molecules of the cell,
and the majority of cellular polyamines are bound to poly-
anionic macromolecules such as DNA, RNA, and phospho-
lipids (Igarashi et al, 1982; Davis et al, 1992). Elevated levels
of ODC and increased polyamines are purported to play an
important role in tumorigenesis largely because of the early
induction of ODC by tumor promoters (O’Brien, 1976; Gilm-
our et al, 1986, 1987) and to studies using inhibitors of ODC
(Bollag, 1972; Verma et al, 1980; Weeks et al, 1982; Ta-
kigawa et al, 1983). For instance, a-difluoromethylornithine
(DFMO), a specific and irreversible inhibitor of ODC enzyme
activity, inhibits the development of skin tumors in carcin-
ogen-treated mice when it is given during the promotion
phase (Weeks et al, 1982; Takigawa et al, 1983).
Previous studies using the keratin 6 (K6)/ODC transgenic
mouse have shown that elevated levels of ODC directed to
the outer root sheath cells of hair follicles using a K6 pro-
moter over the lifetime of the animal lead to hair follicle
degeneration and the subsequent formation of follicular
cysts in the dermis (Megosh et al, 1995). The epithelial cells
lining the follicular cysts express high levels of ODC and
demonstrate a high proliferative index (Gilmour et al, 1999).
By crossing the K6/ODC transgenic mouse with the Tg.AC
v-Ha-ras transgenic mouse, we have demonstrated that el-
evated levels of ODC and polyamines cooperate with a
mutated Ha-ras gene to promote epithelial tumor formation
and invasion in mice (Smith et al, 1998). It is not known,
however, as to how the abnormal skin phenotype of the K6/
ODC transgenic mouse may contribute to changes in pro-
liferation and tumorigenesis. For instance, the K6/ODC
transgene is expressed throughout most of the develop-
ment and lifetime of the mouse. In order to study the effects
of elevated levels of ODC enzyme activity and polyamines
on epidermal cells residing in normal adult skin with no hair
loss, we have generated a transgenic mouse model in
which an inducible form of ODC is targeted to suprabasal
epidermal cells by an involucrin promoter. Suprabasal cells
in intact, normal adult skin are no longer proliferating and
are committed to differentiate terminally. Normally ODC is
expressed, in basal proliferating cells in the epidermis. Cy-
cling cells that express high levels of ODC, however, can be
found also in suprabasal layers of skin tumors. Using
transgenic mice with inducible epidermal ODC, we sought
to determine whether forced ODC induction in suprabasal
cells in the interfollicular epidermis of adult mice is sufficient
to activate these cells. We show that de novo induction of
ODC enzyme activity in adult mouse skin stimulates kera-
Abbreviations: BrdU, bromodeoxyuridine; DFMO, a-difluoro-
methylornithine; ER, estrogen receptor; FITC, fluorescein isothio-
cyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
HSP90, heat shock protein 90; IL, interleukin; K6, keratin 6; ODC,
ornithine decarboxylase; 4OHT, 4-hydroxytamoxifen; a-SMA, a-
smooth muscle actin
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tinocytes and dermal stromal cells in a manner similar to
that in wounded skin with increased epithelial proliferation
and vascularization.
Results
Generation of ODCER transgenic mice To generate a
transgenic mouse model that inducibly elevates ODC ac-
tivity in the epidermis, a cDNA encoding a truncated murine
ODC protein (Ghoda et al, 1989; Clifford et al, 1995) was
fused in frame to a 4-hydroxytamoxifen (4OHT)-responsive
mutant estrogen receptor (ER) ligand-binding domain (Lit-
tlewood et al, 1995) and then cloned downstream of the
human involucrin promoter (Carroll et al, 1993). Following
pronuclear microinjection, three independent founder lines
were generated, all of which expressed the 85 kDa ODCER
fusion protein in the epidermis (Fig 1A).
All of the ODCER transgenic mice were viable and fertile.
Whereas the ODCER2 line exhibited no detectable pheno-
type, the ODCER1 and ODCER3 transgenic lines eventually
lost their hair and developed follicular cysts in the dermis by
2 mo of age in the absence of 4OHT treatment (Fig 2A,B).
The alopecia found in the ODCER1 and ODCER3 transgenic
lines was accompanied by higher basal ODC enzyme ac-
tivity in their skin compared with that in skin from ODCER2
transgenic mice or normal littermates (Fig 1B). ODCER2
transgenic mice were further characterized since they dem-
onstrated a low basal ODC activity similar to wild-type mice
and a normal skin phenotype with no hair loss or develop-
ment of dermal cysts (Fig 2C) as seen in the ODCER1 and
ODCER3 lines.
Activation of ODCER in suprabasal transgenic epider-
mis We tested whether topical application of 4OHT would
induce ODC enzyme activity in the skin of ODCER2 mice.
Following daily applications of 4OHT (1 mg in 0.1 mL et-
hanol) for up to 21 d, ODC enzyme activity continued to
increase to 8.7 and to 23.4 nmol 14CO2 per h per mg protein
after 2 and 21 d of treatment, respectively (Fig 1C). Addi-
tional studies revealed that the epidermal ODC activity
slowly decreased following discontinuation of 4OHT treat-
ment. Two-thirds of the epidermal ODC activity was de-
creased by 2 wk after 4OHT discontinuation, but the basal
level of ODC activity remained elevated compared with the
basal level of activity before 4OHT treatment (data not
shown). Comparative analysis of the ODC activity in the skin
of the three lines of ODCER transgenic mice and the pre-
viously described K6/ODC transgenic mouse, in which the
ODC transgene is directed to the skin by a K6 promoter,
shows that cutaneous ODC activity is typically induced to
higher levels in ODCER2 transgenic mice treated for 21 d
with 4OHT compared with that seen in constitutively ex-
pressed ODC in the K6/ODC transgenic mouse (Fig 1B).
Involucrin is expressed in the suprabasal layers of the
epidermis and the inner root sheath of hair follicles. We
confirmed the suprabasal localization of the involucrin-reg-
ulated ODC protein and the ER ligand-binding domain of
the encoded ODCER fusion protein by immunohistochem-
istry (Fig 3). As previously seen (Gilmour et al, 1986), basal
levels of endogenous ODC protein are virtually non-detect-
able by immunohistochemical staining in wild-type mouse
epidermis (Fig 3A). ODC staining, however, was detectable
in the suprabasal cells of the interfollicular epidermis and in
the inner root sheath of ODCER2 hair follicles both with and
without treatment with 4OHT (Fig 3B,C). Furthermore,
staining for ER protein was detected in the same supraba-
sal epidermal cells of ODCER2 mice with and without 4OHT
but was not detected in normal littermates treated with
4OHT (Fig 3D–F). This staining pattern was similar to that
found in other transgenic mouse models encoding the c-
Myc-ERTAM protein in which the c-Myc-ERTAM protein is
expressed constitutively in the absence of the 4OHT ligand
but sequestered in an inactive state with the heat-shock-
protein 90 (HSP90) (Pelengaris et al, 1999, 2002). Treatment
with 4OHT leads to HSP90 dissociation and activation of
the ER-chimeric protein.
Analyses of lysates prepared from separated epidermal
and dermal tissue revealed that the induction of ODC ac-
tivity following 14 d of topical 4OHT treatments was specific
in the epidermis and not in the underlying dermis (Fig 4A).
Figure 1
Induction of ornithine decarboxylase (ODC) enzyme activity in
ODCER2 transgenic mice. (A) RIPA lysates were prepared from ep-
idermal (Epi) and dermal (Derm) tissue from non-treated ODCER1,
ODCER2, and ODCER3 transgenic mice and their non-transgenic lit-
termates (normal). Equal amounts of protein were loaded and resolved
by SDS-PAGE and transferred to polyvinylidene difluoride membranes.
ODCER and b-actin protein were detected by immunoblotting. A pro-
tein band between 80 and 90 kDa (corresponding to the ODCER fusion
protein) was detected in transgenic epidermis but not in normal mouse
skin using an antibody specific for mouse estrogen receptor (ER) pro-
tein. (B) ODC activity of total skin from ODCER1-3 transgenic mice,
ODCER2 mice topically treated for 21 d with 4-hydroxytamoxifen
(4OHT), and keratin 6 (K6)/ODC transgenic mice. Skin tissue from three
different founder lines ODCER transgenic mice and their normal litter-
mates as well as from K6/ODC transgenic mice was homogenized and
assayed for ODC enzyme activity by quantifying the production of
14CO2 from L-[
14C]ornithine. (C) Induction of ODC enzyme activity in
total skin of 4OHT-treated ODCER2 transgenic mice. ODC/ER2 mice
were topically treated with 1.0 mg 4OHT in 100 mL ethanol daily for 2, 7,
and 21 d. Total skin was homogenized and assayed for ODC enzyme
activity. ODC enzyme activity is expressed as nmol 14CO2 per h per mg
protein  SD with at least three mice per treatment group.
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The 4OHT-stimulated increase in ODC enzyme activity was
accompanied by increased levels of putrescine in the 4OHT-
treated epidermis compared with vehicle control-treated
ODCER2 epidermis, but not in the dermis (Fig 4B). There
were no significant changes in spermidine or spermine lev-
els following 2 wk of 4OHT treatment in either the epidermis
or dermis of ODCER2 transgenic mice (data not shown).
These results demonstrate the suprabasal activation of the
ODCER protein and subsequent elevated ODC enzyme ac-
tivity and putrescine levels in the adult epidermis of the
ODCER2 transgenic mouse line following topical 4OHT
treatment.
De novo induction of suprabasal epidermal ODC stim-
ulates proliferation To determine the effect of induction of
ODC enzyme activity on epidermal proliferation, in vivo
bromodeoxyuridine (BrdU) labeling was performed in adult
ODCER2 transgenic mice following 7 and 21 d 4OHT treat-
ment. Although 1 wk of topical application of 4OHT resulted
in no significant increase in BrdU-stained nuclei (data not
shown), continued 4OHT treatment for 21 d resulted in a
significantly increased labeling index (Fig 5), with a 4-fold
increase compared with non-treated transgenic skin or
4OHT-treated normal littermate skin. Labeled nuclei were
detected only in the basal layer of interfollicular epidermal
cells and not in the suprabasal compartment. Despite the
increased proliferation index, there were no obvious gross
changes in the skin. Histological examination of ODCER2
transgenic skin following 21 d of 4OHT treatment revealed
an epidermis only one to two additional cell layers thick with
infrequent small areas of mild epidermal hyperplasia.
Since there was no marked epidermal hyperplasia fol-
lowing transient activation of ODC, we analyzed the
ODCER2 transgenic skin for epidermal differentiation mark-
ers following daily topical treatment with 4OHT for 3 wk.
Although immunoblot analysis of skin lysates revealed in-
creased expression of the proliferation marker, proliferating
cell nuclear antigen (PCNA), in 4OHT-treated transgenic skin
compared with non-treated transgenic skin and normal lit-
termate skin, the expression of markers for commitment to
differentiation, including K1, K10, and involucrin, was in-
creased in 4OHT-treated transgenic skin as well (Fig 6).
TUNEL staining revealed no increased apoptosis in the skin
of ODCER2 transgenic mice following treatment with 4OHT
(data not shown). These data suggest that transient activa-
tion of ODC activity stimulates proliferation only in keratin-
ocytes that are not committed to differentiate, i.e. cells in
the basal compartment of the epidermis. This ODC prolif-
erative stimulus, however, results in a mild expansion of the
proliferative compartment that is compensated by a con-
comitant expansion of the differentiated compartment in
4OHT-treated transgenic skin. Thus, expression of differen-
tiation markers is increased as well.
To further determine the effect of ODC overexpression on
differentiation markers in keratinocytes, primary keratin-
ocytes were isolated from ODCER2 transgenic mouse skin
and normal littermate skin. In this cultured system, keratin-
ocytes proliferate when maintained in low-calcium medium
(0.05 mM calcium), but terminally differentiate and cease to
proliferate after calcium is raised to 0.14 mM in the medium.
Expression of K1 and K10 marks an early event that occurs
Figure 2
High basal levels of suprabasal ornithine decarboxylase (ODC)
activity lead to hair loss and dermal cyst formation in ODCER1 and
ODCER3 transgenic mice. Comparison of skin from (A, B) 11-mo-old
ODCER3 transgenic mice never treated with 4-hydroxytamoxifen
(4OHT); (C) a 15-mo-old ODCER2 transgenic mouse never treated
with 4OHT; and (D) a 3-mo-old ODCER2 transgenic mouse topically
treated with 4OHT for 21 d. Note the huge dermal cysts (arrows) and
focal areas of epidermal hyperplasia in the ODCER3 transgenic skin.
Hematoxylin & eosin-stained sections. Scale bars: (A) 50 mm, (B) 100
mm, (C) 50 mm, (D) 40 mm.
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as keratinocytes commit to differentiate terminally, followed
by expression of loricrin (Yuspa et al, 1989). ODC activity
was induced in ODCER2 transgenic keratinocytes following
treatment with 1.0 mM 4OHT. In addition, ODC activity was
higher in the ODCER transgenic keratinocytes following the
switch to 0.14 mM calcium compared with that at low cal-
cium because of calcium activation of the involucrin pro-
moter of the ODCER transgene. Thus, the highest ODC
enzymatic activity was present in the ODCER transgenic
keratinocytes cultured in 0.14 mM calcium and treated with
4OHT. As expected, differentiation markers such as K1 were
induced 24 h following the calcium switch in wild-type
keratinocytes (Fig 7A). Induction of ODC in ODCER2
transgenic keratinocytes partially blocked the calcium in-
duction of K1 and K10 (Fig 7A). At 48 h following the cal-
cium switch, later differentiation markers involucrin and
loricrin were induced in both 4OHT-treated and non-treated
normal and transgenic keratinocytes (Fig 7A). Elevated lev-
els of ODC and polyamines, however, did not rescue the
keratinocytes from a calcium-induced block in DNA syn-
thesis (Fig 7B). These results indicate that elevated levels of
ODC activity do not inhibit the commitment of keratinocytes
to differentiate terminally, but the differentiation program is
moderately altered as evidenced by a partial block in the
induction of early differentiation markers in response to a
calcium switch.
Suprabasal ODC expression in skin triggers angiogen-
esis We examined the effects of transient suprabasal ep-
idermal ODC expression on the blood vessel density in the
underlying dermis. Mice received an injection with fluo-
rescein isothiocyanate (FITC)-lectin to label vessels with
active blood flow. Because of binding of the lectin to end-
othelial cells, the fluorescent staining clearly outlined func-
tional vessels with an open lumen (Fig 8A). Quantitation of
FITC-lectin-labeled endothelial cells revealed marked in-
creases in blood vessel density in 4OHT-treated ODCER2
transgenic skin compared with non-treated transgenic skin
or wild-type littermate skin (Fig 8B). Increased vascularizat-
ion of transgenic skin was observed as early as 2 wk of daily
4OHT treatments. In addition, sections of skin from FITC-
lectin-injected mice were immunofluorescent stained for a-
smooth muscle actin (a-SMA)-positive pericytes. Pericytes
were found to be associated in a uniform layer around many
of the blood vessels as indicated by red fluorescence for
pericytes alone or yellow double fluorescence for vessels
where green FITC-lectin-stained endothelial cells over-
lapped with red-stained pericytes (Fig 8A). Thus, 4OHT in-
duction of ODC activity in ODCER2 transgenics increased
the vascularization of the skin, and many of these newly
formed microvessels were able to recruit pericytes.
Elevated epidermal ODC activates keratinocytes ODC
and polyamines are elevated in skin undergoing tissue re-
modeling in such processes as wound healing and tumor
formation. These conditions are characterized by increased
production of cytokines such as interleukin (IL)-1 (Maas-
Szabowski et al, 2000; Murphy et al, 2000; Freedberg et al,
2001) and altered expression of intermediate filaments such
as K6 and K16 (Freedberg et al, 2001; Komine et al, 2001).
Since tissue remodeling in skin includes increased prolifer-
ation and angiogenesis and altered gene expression, we
Figure 3
Suprabasal induction of ornithine decarboxylase (ODC) and estrogen receptor (ER) protein in ODCER2 transgenic mice. Skin sections from
normal wild-type littermates (A, D) and ODCER2 transgenic mice topically treated with the vehicle control ethanol (B, E) or 4-hydroxytamoxifen
(4OHT) (C, F) for 21 d were immunohistochemically stained using an anti-ODC antibody (A–C) or an anti-ER antibody (D–F). Sections were
counterstained with hematoxylin. Scale bars: (A–D) 50 mm; (E, F) 40 mm.
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examined whether ODC overexpression in the skin of
ODCER2 transgenic mice leads to altered expression of
genes in a manner similar to that seen in wound healing.
Therefore, we screened ODC overexpressing epidermal
cells in ODCER2 transgenic mice for expression of an-
giogenic factors that could affect the endothelial cells di-
rectly. Use of Panomics cytokine and angiogenesis
antibody arrays and immunoblot analyses revealed in-
creased expression of IL-1b with higher ODC activity in
the skin (Fig 9A). ELISA assays confirmed that IL-1b levels
were increased in the skin of 4OHT-treated ODCER2
transgenic mice (Fig 9B).
Another marker of hyperproliferative, activated epidermis
is the induced expression of K6 and extracellular matrix
protein such as tenascin-C (Natali et al, 1991; Latijnhouwers
et al, 1997). RT-PCR analysis confirmed that transient in-
duction of ODC in ODCER epidermis leads to increased
levels of K6b but not K6a mRNA expression (Fig 10A). K6
expression was also increased on the protein level both in
epidermal and dermal extracts of skin from ODCER2
transgenic mice treated for 7 d with 4OHT (Fig 10B).
Immunohistochemical staining revealed increased K6 pro-
tein in the intrafollicular epidermis of 4OHT-treated ODCER2
skin (Fig 11A,B). In addition, focal areas of dermal tenascin-
C staining proximal to the epidermal basement membrane
were observed under sections of epidermis that exhibited
mild hyperplasia in ODCER2 transgenic skin following 4OHT
Figure 4
Induction of ornithine decarboxylase (ODC) activity and putrescine
in the epidermis but not in the dermis of 4-hydroxytamoxifen
(4OHT)-treated ODCER2 transgenic mice. ODCER2 transgenic mice
and their normal wild-type littermates were topically treated with 4OHT
(daily administration of 1.0 mg 4OHT per 0.1 mL ethanol) or the ethanol
vehicle control for 14 d. Lysates of epidermal and dermal tissue from
ODCER2 transgenic mouse skin and non-transgenic littermate (normal)
mouse skin were prepared 24 h after the last treatment and assayed for
A) ODC enzyme activity and B) putrescine levels. ODC enzyme activity
was expressed as nmol 14CO2 per h per mg protein and putrescine
levels were expressed as nmol per mg DNA. Values are means  SD,
and are representative of three separate experiments with at least four
mice per treatment group. po0.02.
Figure5
Transient suprabasal induction of ornithine decarboxylase (ODC)
increases the proliferation of basal cells in the skin of ODCER2
transgenic mice. ODCER2 transgenic mice and their normal wild-type
littermates were topically treated with the ethanol vehicle control or with
4-hydroxytamoxifen (4OHT) for 21 d (n¼ 3 or more animals for each
treatment group). Mice received injections of bromodeoxyuridine
(BrdU) at a dose of 100 mg per g body weight 2 h before sacrifice.
Paraffin-embedded sections were immunostained using an anti-BrdU
antibody. (A) Immunostained skin sections from ODCER2 transgenic
mice that were topically treated 21 d with (A) ethanol or (B) 4OHT. Note
that BrdU-stained nuclei were only detected in the basal cell layer of
the epidermis. Scale bars: 50 mm. (B) BrdU-positive cells per 1000 cells
in the basal layer were counted in three to five sections for each treat-
ment group. The percentage of BrdU-positive cells expressed as the
meanþSD. po0.01.
Figure6
Ornithine decarboxylase (ODC) induction stimulates both prolifer-
ation and differentiation in ODCER2 transgenic mouse skin. RIPA
lysates of total skin tissue from ODCER2 mice (T) and their normal wild-
type littermates (N) were prepared after daily topical treatment with 1.0
mg 4-hydroxytamoxifen (4OHT) per 100 mL ethanol or the ethanol ve-
hicle control for 7 or 21 d. Equal amounts of protein were loaded and
resolved by SDS-PAGE and transferred to polyvinylidene difluoride
membranes. The proliferation marker PCNA and the differentiation
markers keratin 1, keratin 10, and involucrin were detected by immuno-
blotting. Banding pattern is representative of immunoblots with at least
three mice per treatment group. The blot was reprobed for b-actin to
monitor for equal protein loading.
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treatment (Fig 11C,D). Since IL-1b, K6, and tenascin-C ex-
pression are induced in hyperproliferative skin following
wounding (Singer and Clark, 1999), ODC induction of these
genes implies that transient induction of ODC in quiescent
adult epidermis is sufficient to ‘‘activate’’ keratinocytes.
Spontaneous tumor formation Unlike the ODCER2 trans-
genic line, the ODCER1 and ODCER3 transgenic lines
exhibit not only much higher ODC enzyme activity in the
non-induced skin leading to hair loss but also develop focal
areas of epidermal hyperplasia by 6 mo of age (Fig 2A,B).
Moreover, some epithelial cells lining dermal cysts are
moderately hyperplastic in the skin of ODCER3 mice fol-
lowing hair loss. In contrast, older, non-treated ODCER2
mice or ODCER2 mice treated with 4OHT for 3 wk dem-
onstrate no hair loss and only mild epidermal hyperplasia
with short-term treatment with 4OHT (Fig 2C,D). By 10 mo
of age, ODCER1, ODCER2, and ODCER3 transgenic mice
develop cyst-like growths on the tail skin without 4OHT
induction (Fig 12A). In addition, occasionally larger keratin-
filled skin tumors appear on other parts of the body of
ODCER1 and ODCER3 transgenic mice but not the haired
ODCER2 mice. These tumors are benign, highly differenti-
ated cyst-like growths that sometimes regress (Fig 12B,C).
To examine whether suprabasal expression of ODC is
sufficient to promote the development of spontaneous skin
tumors in the presence of an activated ras, ODCER3
transgenic mice were bred with Tg.AC transgenic mice pos-
sessing the v-Ha-ras transgene (Leder et al, 1990). Double
Figure 7
Elevated ornithine decarboxylase (ODC) activity alters calcium-in-
duced differentiation in primary keratinocytes from ODCER2
transgenic mouse skin. Primary keratinocytes were isolated from
the skin of ODCER2 mice and their normal littermates and treated with
1.0 mM 4-hydroxytamoxifen (4OHT) or the ethanol vehicle control for 48
h. At the same time, the calcium concentration was raised to 0.14 mM
in the medium of half the keratinocytes to trigger differentiation. (A)
RIPA lysates were prepared 48 h after the calcium switch and equal
amounts of protein were resolved by SDS-PAGE. Keratin 1, keratin 10,
loricrin, involucrin, and b-actin proteins were detected by immunoblot-
ting. (B) Cell proliferation was assessed by the amount of [3H]thymidine
incorporation (c.p.m.) normalized to micrograms DNA. Values are
means  SD of at least three samples, and are representative of three
separate experiments.
Figure8
Induction of ornithine decarboxylase (ODC) activity stimulates
vascularization in the skin of ODCER2 mice. ODCER2 transgenic
mice (closed bars) and their normal wild-type littermates (open bar)
were treated with 4-hydroxytamoxifen (4OHT) or the ethanol vehicle
control for 14 or 21 d. Mice were injected with 0.1 mL fluorescein
isothiocyanate (FITC)-lectin (1 mg per mL) via the tail vein 5 min before
sacrifice to visualize endothelial cells of functional blood vessels. (A)
Skin tissue was fixed in 4% p-formaldehyde, paraffin-embedded, and
sections were immunohistochemically stained for a-smooth muscle
actin (a-SMA) using a Cy3-labeled secondary antibody, covered with
DAPI mounting medium, and examined by fluorescence microscopy.
Both FITC-lectin-stained blood vessels (green) and a-SMA-positive
pericytes (red) are shown in overlaid fluorescent images (a, b) of skin
from ethanol-treated ODCER2 mice (a, c) and of skin from 4OHT-treat-
ed ODCER2 mice (b, d). DAPI (blue) images are shown for the same
view to identify all nuclei (c, d). The basement membrane is marked
with the white dashed line. Arrows point to overlap (yellow) of pericytes
and endothelial cells of blood vessels. Scale bars: 40 mm. (B) The
amount of endothelial cells (FITC) was quantified by calculating the
fluorescein intensity/field of view using a  10 objective. The data
represent the mean fluorescent area of five fields examined for each
tissue sectionþSD, with three to five separate skin samples from dif-
ferent mice analyzed/each treatment group. po0.02.
ODC STIMULATES PROLIFERATION AND ANGIOGENESIS 607124 : 3 MARCH 2005
transgenic mice developed spontaneous malignant squa-
mous cell carcinomas between 7 and 12 wk of age without
prior 4OHT treatment (Fig 12D). In contrast, ODCER2
transgenic mice bred with Tg.AC transgenic mice did not
form skin tumors unless treated with 4OHT. These tumors
appeared to develop from hair follicles (Fig 12E) and to form
keratoacanthomas (Fig 12F). Thus, suprabasal epidermal
ODC overexpression leads to a mild epidermal hyperplasia
that can, with time, result in the spontaneous formation of
benign tumors but can also rapidly lead to malignant car-
cinomas when combined with a mutated ras oncogene.
Discussion
This study demonstrates that de novo induction of ODC
activity in adult mouse skin stimulates both epidermal pro-
liferation and angiogenesis. Healthy keratinocytes normally
proliferate slowly in the basal layer and differentiate as they
move up through the spinous, granular, and cornified layers
in the epidermis (Eckert et al, 1997; Mischke, 1998). In re-
sponse to wounding or many pathologic conditions, how-
ever, keratinocytes are activated to become migratory,
hyperproliferative cells producing growth factors and
cytokines that, in turn, activate underlying dermal fibro-
blasts and endothelial cells (Romero et al, 1997; Maas-Sza-
bowski et al, 2000; Freedberg et al, 2001). Keratinocyte
activation appears to be initiated by IL-1, and these acti-
vated cells are characterized by upregulation of K6 and K16
(Kupper, 1990; Tomic-Canic et al, 1998; Freedberg et al,
2001; Komine et al, 2001). Our results demonstrating in-
creased proliferation, neovascularization, and elevated ex-
pression of proteins such as IL-1b, K6, and tenascin-C in
4OHT-treated ODCER2 transgenic mouse skin indicate that
elevated polyamine levels activate keratinocytes and stim-
ulate angiogenesis in the dermal layer in a manner similar to
skin responding to a wound.
ODCER2 transgenic mice fortuitously demonstrated a
low basal level of ODC activity similar to wild-type mice. As
a result, ODCER2 mice displayed a normal skin phenotype
with no hair loss or formation of dermal cysts as seen in the
ODCER1 and ODCER3 transgenic lines. The basal ODC
enzyme activity did not correspond to the expression of
ODCER protein in the three transgenic lines. It is likely that
the low ODC basal activity observed in the skin of ODCER2
transgenic mice is associated with a different integration
site of the ODCER transgene in the mouse genome that
influences other interacting proteins that modulate ODC
activity. The ODCER2 transgenic mouse is novel in that it is
the first mouse model in which the effects of de novo in-
duction of polyamine biosynthesis can be studied in normal
adult skin. Indeed, ODC enzyme activity is specifically in-
duced in ODCER2 mouse epidermis following topical treat-
ment with 4OHT.
Although the proliferative index was increased, elevated
levels of epidermal ODC activity over 3 wk time did not lead
to significant epidermal hyperplasia as is seen in wound
healing. Indeed, differentiation markers as well as prolifer-
ation markers were upregulated in 4OHT-treated ODCER2
Figure 9
Induction of ornithine decarboxylase (ODC) activity stimulates in-
terleukin (IL)-1b expression in ODCER2 transgenic skin. ODCER2
transgenic mice and their normal wild-type littermates were treated
topically with 4-hydroxytamoxifen (4OHT) or the ethanol vehicle control
for 21 d. (A) RIPA lysates were subjected to western blotting using
antibodies against IL-1b and b-actin. (B) IL-1b protein levels in skin
lysates from ODCER2 transgenic mice (T) and their normal littermates
(N) were also quantitated by ELISA assay.
Figure10
Upregulation of keratin 6 in the skin of 4-hydroxytamoxifen (4OHT)-
treated ODCER2 transgenic mice. (A) Expression of keratin K6a and
K6b mRNA was examined by reverse transcription-PCR using RNA
extracted from the skin (including both the epidermis and dermis) of
ODCER2 transgenic mice and their normal littermates topically treated
for 7 d with 4OHT or the ethanol vehicle control. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression was included as an
internal control. (B) ODCER2 transgenic mice and normal wild-type
littermates were treated topically with 4OHT for 7 d, and keratin 6 pro-
tein expression was determined in epidermal and dermal RIPA lysates
by immunoblot analysis. The blot was reprobed for b-actin to monitor
for equal protein loading.
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transgenic skin. Furthermore, induction of ODC activity did
not rescue primary ODCER2 keratinocytes from a calcium-
triggered DNA synthesis block, as measured by [3H]thymi-
dine incorporation. De novo induction of suprabasal ODC
activity did not block the commitment of this growing ep-
idermal compartment to differentiate, and BrdU-labeled nu-
clei appeared in only the basal layer of the epidermis
yielding no dramatic epidermal hyperplasia. As has previ-
ously been reported in wound-healing studies in wild-type
mice (Mansbridge and Knapp 1987; Paladini et al, 1996), the
induction of K6 expression in the interfollicular epidermis
correlated with less K1 and K10 induction in 4OHT-treated
ODCER2 keratinocytes. A major difference between Myc or
Ras-inducible transgenic mouse models (Pelengaris et al,
1999; Tarutani et al, 2003) and the ODCER2 transgenic
model is that induction of ODC does not appear to inhibit
differentiation of post-mitotic keratinocytes. In contrast,
transient induction of c-Myc in the suprabasal layers of the
Figure12
Tumor formation in ODCER transgenic mice. ODCER3 transgenic
mice (A–C) develop spontaneous, benign skin tumors by 6–10 mo of
age. Black arrows point to follicular cysts that develop in the dermis of
ODCER3 mice following hair loss. Double transgenic mice, generated
by breeding ODCER3 transgenic mice with Tg.AC v-Ha-ras transgenic
mice, develop spontaneous malignant carcinomas between 7 and 12
wk of age (D). In contrast, skin tumors develop in ODCER2 transgenic
mice crossed with Tg.AC v-Ha-ras transgenic mice (E, F) following 5 wk
of topical 4-hydroxytamoxifen treatment with the skin tumors arising
from hyperplasia of perifollicular cells (blue arrow) to form keratoa-
canthomas (F). hematoxylin & eosin-stained sections. Scale bars: (A,
C–F) 50 mm, (B) 150 mm.
Figure 11
Elevated levels of epidermal ornithine decarboxylase (ODC) activ-
ity induce focal areas of keratin 6- and tenascin-C-stained cells in
transgenic skin. ODCER2 transgenic mice were topically treated for
21 d with 4-hydroxytamoxifen (4OHT) (B, D) or the ethanol vehicle
control (A, C). Paraffin skin sections were immunostained using a po-
lyclonal antibody that recognizes both the a and b isoforms of keratin 6
(A, B) or using a polyclonal antibody against tenascin-C (C, D). Arrows
point to stained cells. Scale bars: 50 mm.
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epidermis blocks differentiation and also triggers prolifera-
tion of post-mitotic epidermal cells that have already begun
their differentiation program (Pelengaris et al, 1999). Unlike
ODCER2 transgenic mice where ODC overexpression
stimulates both proliferation and differentiation, Ras and
Raf activation suppress in vivo epidermal differentiation
(Tarutani et al, 2003).
Our results show that elevated levels of polyamines ac-
tivate keratinocytes, but do not transform keratinocytes
over a short time as has been reported for other transgenic
mouse models in which c-Myc, Ras, or Raf were induced in
the epidermis (Pelengaris et al, 1999; Tarutani et al, 2003).
Sustained c-Myc stimulation of epidermal proliferation re-
sulted in benign skin tumors and marked angiogenesis
(Pelengaris et al, 1999). Similarly, the transient activation of
Ras or its downstream effector Raf in mouse epidermis
promoted the hyperproliferative phenotype characteristic of
benign papillomas (Tarutani et al, 2003). Although 21 d of
4OHT induction did not lead to skin tumors in ODCER2
mice, epidermal hyperplasia and spontaneous benign skin
tumors developed in ODCER1 and ODCER3 mice that pos-
sess higher basal epidermal ODC activity compared with
ODCER2 mice. Thus, elevated levels of epidermal ODC
activity over a longer time lead to the development of be-
nign skin tumors. Interestingly, administration of the ODC
inhibitor DFMO to Inv/MycER transgenic mice partially in-
hibited the formation of tumors (S. Pelengaris, personal
communication). ODC is known to be transactivated by c-
myc (Bello-Fernandez et al, 1993; Ben-Yosef et al, 1998),
and topical 4OHT treatment reportedly upregulated ODC
mRNA in the skin of Inv/MycER transgenic mice (Pelengaris
et al, 1999). Although Myc transactivates a number of genes
in addition to ODC (Ben-Yosef et al, 1998), these observa-
tions suggest that upregulation of ODC and polyamines
plays an essential role in Myc-induced skin tumorigenesis.
In view of our data demonstrating the rapid development of
spontaneous carcinomas in ODC/Ras double transgenic
mice and the chemopreventive activity of DFMO in tumor
formation in Inv/MycER transgenic mice, elevated polya-
mine levels appear to cooperate with altered expression
of a signaling pathway that is perhaps in common to and
triggered by both Myc and Ras activation to promote skin
tumorigenesis. Moreover, ODC-induced activation of epi-
dermal cells not only promotes early stages of skin tumori-
genesis but also later stages requiring invasion to
surrounding tissues since squamous cell carcinomas spon-
taneously develop in double transgenic mice expressing
both an ODC and a v-Ha-ras transgene.
Previous studies using the K6/ODC transgenic mouse, in
which a K6 promoter drives the expression of ODC in the
outer root sheath cells of hair follicles, show that continuous
increased expression of epidermal ODC leads to increased
vascularization of the underlying dermis (Lan et al, 2000).
K6/ODC mouse skin is, however, a gross distortion of nor-
mal skin architecture because of disruption of the hair cycle
resulting in the development of dermal cysts as the hair
follicles degenerate. Although the K6/ODC transgenic
mouse is a useful model, the altered skin morphology may
complicate the interpretation of biological effects resulting
from high polyamine levels. Since the epidermal cells that
line the follicular cysts in K6/ODC transgenic mice express
very high levels of ODC, we questioned whether the in-
creased vascularization of the K6/ODC dermis is influenced
by the close proximity of ODC overexpressing cells and
endothelial cells found in the dermis. One of the unique
strengths of the ODCER2 transgenic mouse model is that
ODC activity is induced de novo in adult skin, thus main-
taining a normal skin phenotype without the hair loss or the
resulting development of follicular cysts that is character-
istic of other transgenic mice with altered polyamine me-
tabolism. Although 4OHT treatment increased putrescine
levels in only the epidermis and not in the underlying dermis,
it is possible that the increased vascularization of ODCER2
transgenic skin may, in part, result from polyamines diffus-
ing to the dermal compartment and directly activating end-
othelial cells.
Most likely the increased vascularization in the dermis
results from angiogenic factors that are produced and se-
creted by keratinocytes as a consequence of increased
ODC activity. As part of a normal response to damage or
wounding, proliferating keratinocytes secrete angiogenic
factors (Martin, 1997). As is found in wound healing when
keratinocytes first become activated by the release of IL-1
(Freedberg et al, 2001), this study reveals that induction of
epidermal ODC increases the levels of IL-1. IL-1b has been
shown to be a proangiogenic factor in solid tumors (Voronov
et al, 2003). Moreover, IL-1b can upregulate VEGF and
downregulate the anti-angiogenic factor angiopoietin-1,
thus promoting neovascularization of a tissue (Fan et al,
2004). Cytokines released by activated keratinocytes can
recruit inflammatory cells including macrophages and mast
cells, which have been shown to express MMP-2 and MMP-
9 coinciding with the angiogenic switch in pre-malignant
skin lesions (Coussens et al, 2000). Although focal areas of
4OHT-treated ODCER2 skin showed increased numbers of
mast cells in the underlying dermis compared with non-
treated ODCER2 skin (data not shown), we have no evi-
dence that increased inflammatory cells are responsible for
the increased angiogenesis induced by elevated epidermal
ODC activity. Since angiogenesis is determined by the bal-
ance of both pro-angiogenic and anti-angiogenic factors,
work is underway to determine polyamine-modulated fac-
tors that are responsible for the increased vascularization in
ODCER2 skin.
Another consequence of ODC induction in adult skin is
the early induction of K6, which is associated with hyper-
proliferative conditions. It has been suggested that changes
in the composition of the cytoskeleton may enhance ker-
atinocyte motility and/or hyperproliferation (Wawersik and
Coulombe, 2000; Komine et al, 2001). On the RNA level, the
K6b isoform is selectively induced when polyamine levels
are increased. It is interesting that previous studies have
shown that whereas the K6a isoform mRNA predominates
in the intact epithelia, the K6b mRNA is induced to a sig-
nificantly greater extent following injury or treatment of skin
with phorbol esters (Takahashi et al, 1998; Rothnagel et al,
1999). IL-1 has been reported to induce the transcription of
K6 as part of the activation of keratinocytes in pathologic
conditions such as wound healing, tumors, psoriasis, and
other inflammatory disorders (Komine et al, 2001).
Tenascin-C, a large complex protein of the extracellular
matrix, is expressed transiently at high levels during devel-
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opment and then strongly upregulated during tissue re-
modeling processes such as tumorigenesis and wound
healing (Chiquet-Ehrismann et al, 1986; Sakakura and
Kusano, 1991; Hanamura et al, 1997; Jones and Jones,
2000). That increased polyamine biosynthesis is responsible
for the localized detection of tenascin-C in 4OHT-treated
ODCER2 transgenic skin is corroborated by our observation
that elevated levels of polyamines stimulate tenascin-C ex-
pression in cultured ODC-overexpressing primary keratin-
ocytes (data not shown). Dermal tenascin-C expression has
been shown to be strongly induced in dermal tissue adja-
cent to hyperproliferative epidermis during wound healing
(Latijnhouwers et al, 1996). In addition, tenascin-C has been
implicated in angiogenesis, the regulation of VEGF (Tanaka
et al, 2004), and in modulating cell adhesion and cell motility
(Swindle et al, 2001; Midwood et al, 2004; Mukaratirwa et al,
2004). Thus, as a consequence of increased polyamine
biosynthesis, keratinocytes become more proliferative and
release cytokines and extracellular protein such as tena-
scin-C that, in turn, could activate stromal cells to stimulate
angiogenesis.
This study reveals that the expression of many charac-
teristic markers of wound healing in skin, including IL-1, K6,
and tenascin-C, is induced in non-wounded skin with high
levels of epidermal polyamines. Polyamine activation of
keratinocytes and underlying stromal cells is an early event
in the tumor process that would create a more permissive
microenvironment for tumor development. The ODCER2
transgenic mouse model is valuable in that it can be used to
further investigate how these early changes in polyamine
levels in a normal skin tissue can affect the expansion of
dormant, genetically altered epidermal cells to a malignant
phenotype.
Materials and Methods
Construction of involucrin-ODCER transgene The hormone-
binding domain of the modified murine ER was fused in frame at
the 30 end of a cDNA encoding amino acids 1–426 of a truncated
murine ODC protein (Littlewood et al, 1995), previously shown to
undergo less rapid intracellular protein degradation (Ghoda et al,
1989), in the plasmid pcDNA3.1 (Clontech, Palo Alto, California).
The involucrin promoter construct pH3700-pL2 (Carroll et al, 1993)
consists of 2.5 kb of the human involucrin upstream region, the
involucrin intron, an SV40 intron, and an SV40 polyadenylation se-
quence. The ODCER DNA was verified by sequencing, excised
from pcDNA3.1/ODCER at the AflII and NotI sites, blunt-ended
with T4 DNA polymerase, and cloned in the correct orientation into
the blunt-ended NotI site of the involucrin expression vector
pH3700-pL2 to form pH3700-pL2/ODCER.
Generation of transgenic mice The involucrin-ODCER transgene
was excised from the pH3700-pL2 cloning vector by digestion with
KasI and AseI, purified, and microinjected into fertilized B6C3F2
oocytes using standard protocols. After birth, transgenic mice
were confirmed by PCR analysis of toe genomic DNA. The ODCER
transgene was identified by using specific oligo 1 (50-CCAGGCA-
GATACTATGTCGCATCAG) that binds in the ODC coding region
and oligo 2 (50-GGTTCAGCATCCAACAAGGCAC) that recognizes
the modified ER. Each founder line was backcrossed to C57Bl/6
mice for at least five generations. To activate ODCER in the skin of
adult transgenic mice, 1 mg of 4OHT dissolved in ethanol (1.0 mg
per 0.1 mL) was topically applied each day to a shaved area of the
dorsal skin. Genetically matched wild-type littermates were treated
in the same way as controls in all experiments. Double transgenic
ODCER/Ras mice were derived by breeding ODCER transgenic
mice with Tg.AC transgenic mice possessing the v-Ha-ras trans-
gene (Leder et al, 1990; Hansen et al, 1996). Two hours before
sacrifice, all mice were injected i.p. with BrdU (Sigma Chemical, St
Louis, Missouri) at a dose of 100 mg per g body weight. The animal
protocol for this study was approved by Institutional Animal Care
and Use Committee of the Lankenau Institute for Medical Research
in accordance with the current US Department of Agriculture, De-
partment of Health and Human Service regulations and standards.
Preparation of skin and tumor homogenates Skin and tumor
tissues from transgenic and normal littermates were frozen in liquid
nitrogen, ground to a fine powder, and stored at 801C for sub-
sequent protein and polyamine analyses. In some cases, the ep-
idermis and dermis were separated by plunging excised skin into
551C water for 20 s followed by scraping. For ODC enzyme activity
assays, the epidermal, dermal, and tumor tissues were homoge-
nized in 25 mM Tris-HCl, pH 7.5, 2.5 mM dithiothreitol, 0.1 mM
EDTA, and protease inhibitors including 1 mg per mL each of apr-
otinin, leupeptin, pepstatin, 1 mM sodium orthovanadate, 1 mM
sodium fluoride, and 1 mM pefabloc. Homogenates were assayed
for ODC enzyme activity by quantifying the production of 14CO2
from L-[14C]ornithine (New England Nuclear, Boston, Massachu-
setts) as previously described (O’Brien et al, 1975). For polyamine
analyses, ground tissues were homogenized in 0.2 N perchloric
acid and incubated at 41C overnight. Dansylated polyamines were
separated on a reversed-phase C18 HPLC column (Koza et al,
1991). Polyamine values were normalized for the amount of DNA in
the tissue extracts.
Primary cultures of epidermal cells Primary cultures of epider-
mal cells were isolated from 3- to 4-d-old ODCER transgenic
newborn pups and their normal littermates by a trypsin flotation
procedure (Yuspa and Harris, 1974; Hennings et al, 1980). ODCER
transgenic pups were distinguished from their normal littermates
by PCR genotyping for the ODCER transgene. Cells were plated at
3.0  106 cells per 60 mm dish or onto glass coverslips in low-
calcium keratinocyte media (EMEM w/o calcium, BioWhittaker
Walkersville, Maryland) supplemented with 8% chelex-treated fetal
bovine serum and 0.05 mM calcium) and grown at 351C with 5%
CO2. To induce terminal differentiation, the calcium concentration
was raised to 0.14 mM calcium, and the cells were harvested 24 h
later. To induce ODC enzyme activity in the ODCER transgenic
keratinocytes, cells were treated with 1.0 mM 4OHT for 24–48 h.
Immunoblot analyses Tissue or keratinocytes were homogenized
in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% (w/v)
deoxycholic acid, 1% (w/v) NP-40, 1 mM EDTA, containing 1 mg
per mL each of aprotinin, leupeptin, pepstatin, 1 mM sodium or-
thovanadate, 1 mM sodium fluoride, and 1 mM pefabloc), and
passed through a syringe needle multiple times after a 45 min
incubation on ice. Lysates were clarified by centrifugation at
15,300  g. for 10 min, and the protein content was determined
using the Bio-Rad D/C protein assay kit (Bio-Rad Laboratories,
Hercules, California). Protein was separated by SDS-PAGE, trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Millipore,
Bedford, Massachusetts), and briefly stained with Ponceau S (Si-
gma Chemical) to verify efficient transfer. Immunoblots were incu-
bated for 1 h in blocking solution (phosphate-buffered saline (PBS)
with 10% non-fat dry milk and 0.05% Tween 20) followed by a 2 h
incubation with the primary antibody diluted in PBS with 0.1% milk
and 0.05% Tween 20. Blots were probed with a rabbit polyclonal
K1, K10, K6, loricrin, or involucrin antibody (Covance, Richmond,
California), a monoclonal anti-PCNA antibody (Santa Cruz Bio-
technology, Santa Cruz, California), a rabbit polyclonal anti-ER
antibody (NeoMarkers, Fremon, California), or a rabbit polyclonal
anti-IL-1b antibody (R&D Systems, Minneapolis, Minnesota). Filters
were reprobed with antibodies against b-actin or tubulin (Sigma
Chemical) to verify equal loading of protein. Bound antibodies
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were visualized using enhanced chemiluminescence (Amersham
Pharmacia Biotech, Piscataway, New Jersey).
Immunohistochemistry/immunoﬂuorescence Tissues were
fixed in 4% p-formaldehyde in PBS overnight and embedded in
paraffin. Sections of all tissues were stained with hematoxylin &
eosin for histopathological evaluation. Sections were deparaffini-
zed, hydrated, and incubated with primary antibody. Primary an-
tibodies used included a rabbit polyclonal antibody against ER
(NeoMarkers), rabbit polyclonal antibody against K6 (Covance), a
rabbit polyclonal antibody against tenascin-C (Chemicon, Terne-
cula, California), a monoclonal antibody against a-SMA (Biomeda,
Foster City, California), and a rabbit antibody against ODC (a kind
gift from Oili Heitala, University of Oulu, Finland). Slides were then
incubated with the appropriate biotinylated secondary antibody
and then with an avidin and biotinylated peroxidase complex
(Vectastain Elite ABC kit, Vector Laboratories, Burlingame, Califor-
nia). Immunoreactive cells were localized by incubating the sec-
tions with a chromagen solution containing diaminobenzidine and
peroxide and then counterstaining with hematoxylin.
BrdU incorporated in cells undergoing DNA synthesis was de-
tected in tissue sections using a kit from Zymed Laboratories (San
Francisco, California). Deparaffinized sections were pretreated
with 0.1% trypsin for 10 min, blocked with rabbit serum, and then
incubated with a rat monoclonal anti-BrdU antibody (Zymed Lab-
oratories) for 2 h at room temperature. The sections were then
incubated with a biotinylated goat anti-mouse antibody (Zymed
Laboratories) followed by an avidin–biotin–peroxidase complex,
revealed in the presence of diaminobenzidine and then counter-
stained with Mayer’s hematoxylin. The number of BrdU-positive
nuclei in the basal layer of the epidermis was counted in a total
number of at least 1000 basal cells per tissue section under  200
magnification. The proliferative index was determined by multiply-
ing the number of BrdU-positive cells/total number of counted
basal epidermal cells by 100. Sections were also examined for
apoptosis using the terminal deoxynucleotidyl transferase-mediat-
ed nick end labeling assay according to the instructions of the
manufacturer (Apoptag Apoptosis Detection Systems, Serologicals
Corp., Norcross Georgia).
For the detection of a-SMA-reactive pericytes and open (func-
tional) endothelial cells in the same histological sections, immuno-
fluorescence staining was performed on paraffin-embedded
sections of skin obtained from mice injected i.v. with FITC-lectin
(binds to endothelial cells) just prior to sacrifice. Paraffin-embed-
ded sections were deparaffinized, steamed in 0.1 mM sodium cit-
rate, pH 6.0 for 10 min, and incubated with a monoclonal antibody
specific for a-SMA (Biomeda) followed by incubation with second-
ary antibody conjugated to Cy3 (Jackson ImmunoResearch Labs,
West Grove, Pennsylvania). Sections were covered with coverslips
mounted with Vectashield mounting medium containing DAPI
(Vector Laboratories) to counterstain DNA and to visualize the nu-
clei of all cells. Immunostained sections were examined by fluo-
rescence microscopy using a Zeiss Axiovert 220M microscope
(Carl Zeiss, Inc, Thornwood, New York) powered by Axiovision 4.0
software with multi-channel, Z-stack acquisition and 3D deconvo-
lution and analyzed for red (a-SMA) and green (FITC-lectin).
ELISA IL-1b levels of tissue lysates from ODCER2 transgenic
mice and their normal littermates were measured. IL-1b pro-
tein levels in RIPA skin lysates were assayed using a mouse
IL-1b-specific ELISA (Quantikine; R&D Systems) normalized to
total protein content measured by the Bradford assay (Bio-Rad
Laboratories).
RT-PCR analysis Total RNA was isolated from the skin of normal
and transgenic mice using TriReagent (Molecular Research Center,
Cincinnati, Ohio). Two micrograms of total RNA was reverse-tran-
scribed using Super Script II RNase H reverse transcriptase (Life
Technologies, Gaithersburg, Maryland) and random hexamer prim-
er (Amersham Pharmacia Biotech) at 421C for 1 h for cDNA syn-
thesis. The reverse transcription product was diluted 15-fold in
water, and 10 mL was used as a template for PCR amplification.
PCR was performed under standard conditions in a 50 mL reac-
tion mix containing Red Pol polymerase (Gene Choice, Frederick,
Maryland), nucleotides, and primers for either K6a or K6b. A
constitutively expressed gene, glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), was used as an internal control, generating
a 600 bp PCR product. Briefly, the reactions comprised of 2 min of
an initial denaturation step (951C) followed by 30 cycles of dena-
turation (951C, 30 s), annealing (551C, 30 s), and extension (721C,
1 min) followed by a final elongation step of 5 min at 721C. Twenty
microliters of PCR products were electrophoresed on 2% agarose
gels. The specific primer pairs used were:
For GAPDH:
forward primer, 50-TGCTGAGTATGTCGTGGAGTC-30
and reverse primer, 50-AGTGGGAGTTGCTGTTGAAGT-30
For K6a:
forward primer, 50-AAATACACCACCACCTCCTCCAGC-30
and reverse primer, 50-AGCCTGCCACCCAAATACAAC-30
For K6b:
forward primer, 50-CACCATCAAATACACCACCAGCG-30
and reverse primer, 50-AAGCAGCCAAAAAGAGAAGCGAG-30
Quantitation of dermal vascularization The skin vasculature
was visualized by fluorescent angiography using FITC-labeled
lycopersicon esculentum lectin (Vector Laboratories) injected i.v.
(100 mg in 100 mL of PBS) via the tail vein of mice 5 min before
sacrifice (Inoue et al, 2002). Skin tissues were fixed in 4% p-for-
maldehyde and paraffin embedded. Sections were deparaffinized
and hydrated, and then cover slips were mounted on slides with
Vectastain containing DAPI, sealed, and examined using a Zeiss
microscope. All tissues and sections were processed under sub-
dued light. Images were recorded using an Axiocam digital cam-
era, and images of representative views from each section as well
as an area away from the tissue to determine background fluo-
rescence were taken using a  10 objective. To analyze each im-
age for fluorescence intensity, a region in the dermal tissue was
circumscribed that excluded the epidermis and hair follicles be-
cause of autofluorescence of hair. The mean value of fluorescent
intensity of five highlighted areas of each section was calculated as
the vessel density for each section using a Macro written for the
KS300 imaging software (Zeiss).
Statistical analyses Data are expressed as mean  SD. Com-
parison of two groups was carried out with an unpaired, two-tailed
Student’s t test. A value of po0.05 was considered statistically
significant.
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